Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sars-Cov-2 Antibody Response After Bbibp-Corv (Sinopharm) Vaccination in Cancer Patients: A Case-Control Study Publisher



Safarnezhad Tameshkel F1 ; Abedin Dargoush S2 ; Amirkalali B1 ; Javadi S3 ; Ghiaseddin A4 ; Alimohamadi Y5 ; Basi A6 ; Jamshidi Makiani M7, 8 ; Zamani F1 ; Karbalaie Niya MH1, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Stem Cell and Regenerative Medicine Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Internal Medicine, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Chemistry, Michigan State University, East Lansing, MI, United States
  5. 5. Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
  6. 6. Department of Hematology and Oncology, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Antimicrobial Resistant Research Center, Iran University of Medical Sciences, Tehran, Iran
  8. 8. Department of Infectious Disease, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran
  9. 9. Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Medicine Published:2023


Abstract

Background: Long-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. In the present prospective study, we aimed to evaluate severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody response with BBIBP-CorV vaccine in Iranian cancer patients. Methods: All the patients registered to receive BBIBP-CorV (Sinopharm) vaccine were divided into two groups of with (cases = 107) and without (controls = 45) history of cancer. Serum levels of SARS-CoV anti-spike recombinant receptor binding domain (anti-sRBD) and anti-nucleocapsid (anti-N) IgG serum levels were measured on days 0 (phase 0), 28–32 (phase I), and 56–64 (phase II) of vaccination. The data were analyzed using SPSS, version 22. Results: Totally, 152 individuals (67.1% females) with the mean age of 46.71 ± 15.36 years were included. Solid cancers included 87.8% of the cancer cases (46.7% gynecological and 31.8% gastrointestinal cancer). At Phases I and II, positive anti-sRBD IgG and anti-N IgG were significantly lower among the cases in total analysis. Side effects were not significantly different between the cases and controls. The lowest positive anti-sRBD IgG test was observed among the cancer patients who were simultaneously receiving chemotherapy (35.3%). Anti-sRBD IgG and anti-N IgG serum levels significantly increased at phases I and II in total analysis and in each group. In addition, serum anti-sRBD IgG increased during the three phases and it was significantly higher in the control group. Conclusion: Full vaccination of COVID-19 by BBIBP-CorV in immunocompromised patients such as cancer patients is safe and effective and could induce antibody response but in lower levels compared to healthy people. Probable causes to have minor antibody response found in males, older ages, individuals with BMI ≥ 25, those without past history of COVID-19 and with hematologic cancers. No significant side effects after vaccination were seen. Copyright © 2023 Safarnezhad Tameshkel, Abedin Dargoush, Amirkalali, Javadi, Ghiaseddin, Alimohamadi, Basi, Jamshidi Makiani, Zamani and Karbalaie Niya.
Related Docs
View other Related Docs
1. Seroconversion Following the First, Second, and Third Dose of Sars-Cov-2 Vaccines in Immunocompromised Population: A Systematic Review and Meta-Analysis, Virology Journal (2022)
2. Immunogenicity of Covid-19 Mrna Vaccines in Immunocompromised Patients: A Systematic Review and Meta-Analysis, European Journal of Medical Research (2022)
3. A Systematic Review and Meta-Analysis of Immune Response Against First and Second Doses of Sars-Cov-2 Vaccines in Adult Patients With Hematological Malignancies, International Immunopharmacology (2022)
4. Challenges Posed by Covid-19 in Cancer Patients: A Narrative Review, Cancer Medicine (2022)
5. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)
6. Covid-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran, Vaccines (2022)
7. Vlp-Based Covid-19 Vaccines: An Adaptable Technology Against the Threat of New Variants, Vaccines (2021)
8. Short-Term Sars-Cov-2 Re-Infection Rate in Vaccinated Health Workers Based on Received Vaccines: A Cross-Sectional Study, Current Respiratory Medicine Reviews (2023)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (8)
Mohammadreza Salehi (2)
Other Related Docs
9. Diagnostic Performance of a Novel Antigen-Capture Elisa for the Detection of Sars-Cov-2, Analytical Biochemistry (2023)
10. Covid-19 Vaccinations: The Unknowns, Challenges, and Hopes, Journal of Medical Virology (2022)
11. Safety and Immunogenicity of a Recombinant Receptor-Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine™) Against Covid-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial, Journal of Medical Virology (2023)
12. A Year of Experience With Covid-19 in Patients With Cancer: A Nationwide Study, Cancer Reports (2023)
13. Molecular Variants of Sars-Cov-2: Antigenic Properties and Current Vaccine Efficacy, Medical Microbiology and Immunology (2022)
14. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)
15. Effectiveness of Covid-19 Vaccines Against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies, Vaccines (2022)
16. Covid-19 Vaccines Mix-And-Match: The Concept, the Efficacy and the Doubts, Journal of Medical Virology (2022)
17. Association of Sars-Cov-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-Analysis, JAMA Otolaryngology - Head and Neck Surgery (2023)
18. The Effectiveness of Covid-19 Vaccines in Reducing the Incidence, Hospitalization, and Mortality From Covid-19: A Systematic Review and Meta-Analysis, Frontiers in Public Health (2022)
19. The Quest for a Better Fight: How Can Nanomaterials Address the Current Therapeutic and Diagnostic Obstacles in the Fight Against Covid-19?, Journal of Drug Delivery Science and Technology (2022)
20. Acute Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia Post Covid-19 Vaccination; a Systematic Review, Journal of the Neurological Sciences (2022)
21. Covid-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in Covid-19-Vaccinated Patients: A Multicenter Comparative Cohort Study, Arthroplasty Today (2022)
22. Short-Term Safety of Covaxin, Sinopharm, Sputnik V, and Astrazeneca Covid-19 Vaccines Among Iranian Healthcare Workers: A Cross-Sectional Study, Archives of Clinical Infectious Diseases (2024)
23. Sars-Cov-2 Infection in Cancer Patients, Susceptibility, Outcome and Care, American Journal of the Medical Sciences (2022)
24. Aging & Covid-19 Susceptibility, Disease Severity, and Clinical Outcomes: The Role of Entangled Risk Factors, Experimental Gerontology (2021)
25. Immunologic Response, Efficacy, and Safety of Vaccines Against Covid-19 Infection in Healthy and Immunosuppressed Children and Adolescents Aged 2 – 21 Years Old: A Systematic Review and Meta-Analysis, Journal of Clinical Virology (2022)
26. A Case of Covid-19 Infection in a Kidney Transplant Recipient After Receiving the Single Dose of Covid-19 Vaccination, Annals of Medicine and Surgery (2022)
27. The Effect of Covid-19 Mrna Vaccines Against Postvaccination Laboratory-Confirmed Sars-Cov-2 Infection, Symptomatic Covid-19 Infection, Hospitalization, and Mortality Rate: A Systematic Review and Meta-Analysis, Expert Review of Vaccines (2022)
28. Anti-Cancer Effect of Covid-19 Vaccines in Mice Models, Life Sciences (2023)
29. Side Effects and Short-Term Safety of Covid-19 Vaccines for Pregnant Women: A Case Study of Southeast Iran, Archives of Clinical Infectious Diseases (2023)
30. Characterization of Stability, Safety and Immunogenicity of the Mrna Lipid Nanoparticle Vaccine Iribovax® Against Covid-19 in Nonhuman Primates, Journal of Controlled Release (2023)
31. Breakthrough Sars-Cov-2 Infections After Vaccination: A Critical Review, Human Vaccines and Immunotherapeutics (2022)
32. Safety and Immunogenicity of Corenapcin, a Sars-Cov-2 Mrna Vaccine, As a Fourth Heterologous Booster in Healthy Iranian Adults: A Double-Blind, Randomized, Placebo-Controlled, Phase 1 Clinical Trial With a Six-Month Follow-Up, International Immunopharmacology (2024)
33. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
34. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)
35. The Clinical Impact of Mrna Therapeutics in the Treatment of Cancers, Infections, Genetic Disorders, and Autoimmune Diseases, Heliyon (2024)
36. Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients, Iranian Journal of Allergy# Asthma and Immunology (2024)
37. Acceptance or Rejection of the Covid-19 Vaccine: A Study on Iranian People’S Opinions Toward the Covid-19 Vaccine, Vaccines (2022)
38. Delving Into Revolutionary Sars-Cov-2 Vaccine Approaches: Molecular and Virological Examinations; Principles of Sars-Cov-2 Vaccine Platform; [Adentrandose En Enfoques Revolucionarios De Vacunas Sars-Cov-2: Examenes Moleculares Y Virologicos; Principios De La Plataforma De Vacunas Sars-Cov-2], Vacunas (2024)
39. Risk of Flare or Relapse in Patients With Immune-Mediated Diseases Following Sars-Cov-2 Vaccination: A Systematic Review and Meta-Analysis, European Journal of Medical Research (2024)
40. Sudden Sensorineural Hearing Loss After Receiving an Inactivated Viral Vaccine, Sinopharm: Two-Case Report, SAGE Open Medical Case Reports (2023)
41. Sars-Cov-2 Mrna-Vaccine Candidate; Corenapcin®, Induces Robust Humoral and Cellular Immunity in Mice and Non-Human Primates, npj Vaccines (2022)
42. Appraisal of Sars-Cov-2 Mutations and Their Impact on Vaccination Efficacy: An Overview, Journal of Diabetes and Metabolic Disorders (2022)
43. Current Advances and Challenges in Covid-19 Vaccine Development: From Conventional Vaccines to Next-Generation Vaccine Platforms, Molecular Biology Reports (2022)
44. Evaluation of Seroconversion Rate Following Sars Cov 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences, Avicenna Journal of Medical Biotechnology (2023)
45. Cutaneous Adverse Reactions Following Covid-19 Vaccinations: A Systematic Review and Meta-Analysis, Journal of Cosmetic Dermatology (2022)
46. Association of New-Onset Seizures With Sars-Cov-2 Vaccines a Systematic Review and Meta-Analysis of Randomized Clinical Trials, JAMA Neurology (2024)
47. The Association Between Micronutrients and the Sars-Cov-2-Specific Antibodies in Convalescent Patients, Infection (2022)
48. The Chimera of S1 and N Proteins of Sars-Cov-2: Can It Be a Potential Vaccine Candidate for Covid-19?, Expert Review of Vaccines (2022)
49. Safety and Efficacy of Rcp Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm Bbibp: A Phase Iii, Non-Inferiority Trial, Heliyon (2024)